Abstract
The use of cultured heart cells (primary cultures) has a number of advantages over intact noncultured cardiac muscle preparations, and these advantages have been listed and discussed previously (1). The major advantages include the facts that (a) the cells can be chronically exposed to drugs and other chemicals over long periods; (b) the cells are denervated, and so direct effects of chemicals on the myocardial cells can be assessed; (c) possible effects of chemicals on changes in blood flow can be disregarded; (d) the cultures can be purified so that they consist primarily of myocytes, i.e., preponderantly one cell type; this is especially important for metabolic and biochemical assay studies; and (e) contractions of the monolayer cultures or reaggreate cultures can be directly observed under the microscope. If the cultures are prepared as monolayers, the contractions of individual cells can be observed, and the monolayers make a good preparation, consisting of two compartments (intracellular and extracellular) for ion flux studies. Reaggregate cultures have the advantage of being able to be impaled relatively easily with one or two intracellular microelectrodes for electrophysiological experiments.
The work of the authors and their colleagues reviewed and summarized in this article was supported primarily by grant HL-31942 from the National Institutes of Health.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Sperelakis, N. In: The Coronary Artery (Ed. S. Kalsner), Chapter 9, Croom Helm, Ltd., London, 1980, pp. 118–167.
Piper, H.M., Probst, I., Schwartz, P., Rutter, F.J. and Spieckermann, P.G. J. Mol. Cell. Cardiol. 14: 397–412, 1982.
Jacobson, S.L., Kennedy, C.B. and Mealing, G.A.H. Can. J. Physiol. Pharmacol. 61: 1312–1316, 1983.
Brown, A.M., Lee, K.S. and Powell, T. J. Physiol. 318: 955–977, 1981.
Schneider, J.A. and Sperelakis, N. J. Surg. Res. 16: 389–403, 1974a.
Pappano, A.J. Circ. Res. 27: 379–390, 1970.
Sperelakis, N. In: The Slow Inward Current and Cardiac Arryhthmias (Eds. D.P. Zipes, J.C. Hailey and V. Elharrar), Martinus Nijhoff, The Hague, 1980, pp. 221–262.
Shigenobu, K. and Sperelakis, N. Circ. Res. 31: 932–952, 1972.
Shigenobu, K., Schneider, J.A. and Sperelakis, N. J. Pharmacol. Exp. Ther. 190: 280–288, 1974.
Kohlhardt, M., Hauer, B., Krause, H., and Fleckenstein, A. Pfluegers Arch. 335: 309–322, 1972.
Kohlhardt, M. and Fleckenstein, A. Naunyn-Schmied. Arch. Pharmacol. 298: 267–272, 1977.
Vogel, S., Crampton, R. and Sperelakis, N. J. Pharmacol. Exp. Ther. 210: 378–385, 1979.
Sperelakis, N. Am. Heart J. 107: 347–357, 1984b.
Kerr, L.M. and Sperelakis, N. Am. J. Physiol. 245: C415–C422, 1983.
Gonzalez-Serratos, H., Valle-Aguilera, R. and Phillips, C. In: Calcium Antagonists, Mechanisms of Action on Cardiac Muscle and Vascular Smooth Muscle (Ed. N. Sperelakis), Martinus Nijhoff, Boston, 1984, pp. 317–325.
Kojima, M. and Sperelakis, N. Eur. J. Pharmacol. 94: 9–18, 1983.
Li, T. and Sperelakis, N. Can. J. Physiol. Pharmacol. 61: 957–966, 1983b.
Pang, D.C. and Sperelakis, N. Eur. J. Pharmacol. 87: 199–207, 1983a.
Pang, D.C. and Sperelakis, N. Biochem. Pharmacol. 32: 1660–1663, 1983b.
Hescheler, J., Pelzer, D., Trube, G. and Trautwein, W. Pfluegers Arch. 393: 287–291, 1982.
Pang, D.C. and Sperelakis, N. Eur. J. Pharmacol. 81: 403–409, 1982.
Josephson, I. and Sperelakis, N. Eur. J. Pharmacol 40: 201–208, 1976.
Lynch, C., Vogel, S. and Sperelakis, N. Anesthesiology 55: 360–368, 1976.
Sperelakis, N., Belardinelli, L. and Vogel, S.M. In: Proceedings of VIII World Congress of Cardiology (Eds. S. Hayase and S. Murao), Excerpta Medica, Amsterdam, 1979, pp. 229–236.
Chesnais, J.M., Coraboeuf, E., Sauvain, M.P. and Vassas, J.M. J. Mol. Cell. Cardiol. 7: 627–642, 1975.
Vogel, S. and Sperelakis, N. Am. J. Physiol. 233: 99–103, 1977.
Belardinelli, L., Vogel, S.M.M., Sperelakis, N., Rubio, B. and Berne, H.M. J. Mol. Cell. Cardiol. 11: 877–892, 1979.
Schneider, J.A. and Sperelakis, N. Eur. J. Pharmacol. 27: 349–354, 1974b.
Vogel, S. and Sperelakis, N. Am. J. Physiol. 235:H46–H51, 1978.
Wahler, G.M. and Sperelakis, N. Can. J. PhysiT Pharmacol. 00: 000–000, 1984a.
Taniguchi, J., Noma, A. and Irasawa, H. Circ. Res. 53: 131–139, 1983.
Tsien, B.W, Giles, W. and Greengard, P. Nature (Lon TIT New Biol. 240: 181–183, 1972.
Watanabe, A.M. and Besch, H.R., Jr. Circ. Res. 35: 316–324, 1974.
Sperelakis, N. and Schneider, J.A. Am. J. Cardiol. 37: 1079–1085, 1976.
Reuter, H. and Scholz, H. J. Physiol. (Lond) 264: 49–62, 1977.
Josephson, I. and Sperelakis, N. J. Mol. Cell. Cardiol. 10: 1157–1166, 1978.
Metzger, H. and Lindner, E. Arzneim.-Forsch./Drug Res. 31: 1248–1250, 1981.
Vogel, S. and Sperelakis, N. J. Mol. Cell. Cardiol. 13: 51–64, 1981.
Irasawa, H. and Kokubun, S. J. Physiol. 338: 321–327, 1983.
Li, T. and Sperelakis, N. Circ. Res. 52: 111–117, 1983a.
Bkaily, G., Sperelakis, N., Elishalom, Y. and Barenholz, Y. Am. J. Physiol. 295 (Heart Circ. Physiol. 19): H756–H761, 1984b.
Bkaily, G. and Sperelakis, N. Submitted 1984b.
Nargeot, J., Nerbonne, J.M., Engels, J. and Lester, H.A. Proc. Natl. Acad. Sci. USA 80: 2395–2399, 1983.
Cachelin, A.B., KePeyer, J.E., Kokubun, S. and Reuter, H. Nature 304: 462, 1983.
Trautwein, W. and Hofmann, F. Proc. Internat. Union. Physiol. Sci. 15: 75, 1983.
Bean, B.P., Nowysky, M.C. and Tsien, H.W. Nature 307: 371–375, 1984.
Reuter, H., Stevens, C.F., Tsien, H.W. and Yellen, G. Nature (Lond) 297: 501–504, 1982.
Rinaldi, M.L., Capony, J.-P. and Demaille, J.G. J. Mol. Cell. Cardiol. 14: 279–289, 1982.
Weer, B.J., Pappano, A.J., Peach, M.J., Bing, K.T., McLean, M.J., Vogel, S.M. and Sperelakis, N. Circ. Res. 39: 178–183, 1976.
Brum, G., Flockerzi, V., Hofmann, F., Osterreider, W. and Trautwein, W. Pfluegers Arch. 398: 197–159, 1983.
Bkaily, G. and Sperelakis, N. Am. J. Physiol. 246 (Heart Circ. Physiol. 15): H630–H634, 1984a.
Bkaily, G. and Sperelakis, N. Am. J. Physiol. 246 (Heart Circ. Physiol. 15): H630–H634, 1984a.
Josephson, I. and Sperelakis, N. Eur. J. Pharmacol. 40: 201–208, 1982.
Schneider, J.A. and Sperelakis, N. J. Mol. Cell. CarTol. 7: 249–273, 1975.
Sperelakis, N. In: Calcium-Antagonists and Cardiovascular Disease (Eds. L.H. Opie and H. Krebs), Raven Press, New York, 1984a, pp. 277-Z91.
Sperelakis, N. Membr. Biochem. 5: 131–166, 1984c.
Sperelakis, N. and McLean, M.J. In series: Recent Advances in Studies on Cardiac Structure and Metabolism. Eds. N.S. Dhalla and T. Sano), University Park Press, Baltimore, 1978, 12: 645–666.
Sperelakis, N., Wahler, G.M. and Bkaily, G. In: Regulation of Calcium Transport Across Muscle Membranes (A volume of Current Topics in Membranes and Transport) (Ed. A.E. Shamoo), Academic Press, Inc., New York, in press, 1984.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Sperelakis, N., Bkaily, G. (1985). Regulation of Calcium Slow Channel Function by Metabolism and Cyclic Nucleotides. In: Stone, H.L., Weglicki, W.B. (eds) Pathobiology of Cardiovascular Injury. Developments in Cardiovascular Medicine, vol 49. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2621-2_8
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2621-2_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9639-3
Online ISBN: 978-1-4613-2621-2
eBook Packages: Springer Book Archive